Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Single-blind, Parallel Design, Multi-center, Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)

NCT02855892 is registered in ClinicalTrials.gov with GemVax & Kael as lead sponsor.

NCT NCT02855892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02855892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Single-blind, Parallel Design, Multi-center, Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)
Lead sponsor
GemVax & Kael
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2015
Completion date
October 31, 2016
Enrollment
161 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia (bph)